查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球溶瘤病毒治療市場-2022-2029
市場調查報告書
商品編碼
1143413

全球溶瘤病毒治療市場-2022-2029

Global Oncolytic Virus Therapy Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

溶瘤病毒治療市場預計在預測期間（2022-2029 年）以 19.32% 的複合年增長率增長。

溶瘤病毒是基因工程或天然存在的病毒，它們模仿選定的術語，可以殺死癌細胞，同時保留正常組織。溶瘤病毒療法是一種新型的癌症治療方法，並在全球範圍內取得了可喜的成果。

市場動態

癌症患者數量的增加和溶瘤病毒等癌症治療方法的不斷發展正在推動全球市場的增長。

癌症患者的增加和臨床研究正在推動全球溶瘤病毒治療市場的增長。

不斷上升的癌症病例和越來越多的溶瘤病毒治療臨床研究正在推動全球市場增長。例如，根據 Clinical Trials.Gov，有 10 項介入性臨床研究。根據政府的說法，有 10 項積極的介入臨床研究。其中一些正在接受衛理公會醫院研究所贊助的立體定向放射治療和原位溶瘤病毒治療轉移性三陰性乳腺癌和轉移性非小細胞肺癌的 II 期失去機會試驗，計劃於 2023 年進行。到 11 月結束。美國國家癌症研究所 (NCI) 贊助的 Pexavec 溶瘤病毒聯合免疫檢查點抑製劑治療難治性結直腸癌的 1/2 期研究（計劃於 2023 年 6 月完成），Genelux Inc. 贊助了 1b 期和 2 期研究（ VIRO-15) GL-ONC1 oncortoimmunotherapy 用於復發或難治性卵巢癌患者（預計完成時間：2022 年 12 月）。

此外，據世界衛生組織統計，2020年癌症將導致1000萬人死亡，大約六分之一的人將死於癌症。其中，約70%發生在低收入和中等收入國家，最常見的癌症類型是乳腺癌（2020年226萬例）、肺癌（2020年約221萬例）、結直腸癌（193萬例） 2020 年）。

高成本和免疫反應正在抑制市場增長。

由於重複施用癌症治療藥物而對基於病毒的療法產生的免疫反應已成為製約市場增長的重要因素。溶瘤病毒治療的高成本將進一步影響市場增長，尤其是在新興國家。

COVID-19 的影響

COVID-19 通過創造更好的機會對市場產生了積極影響。例如，COVID-19 引導我們專注於生物技術增強產品以獲得更好的結果。在大流行期間，許多生物製藥行業開發了各種生物技術改進的疫苗來克服大流行，用於治療和診斷 SARS-CoV-2。此外，生物技術設備在抗擊大流行的各個階段都發揮了作用。 COVID-19 大流行已將目光轉向生物技術解決方案，以改善醫療保健系統，這對免疫毒素市場產生了積極影響。

細分分析

預計黑色素瘤細分市場將在預測期內（2022-2029 年）主導全球市場。

黑色素瘤是皮膚黑色素瘤日益嚴重的負擔，FDA 目前正在測試一種單純皰疹病毒 (HSV) 的溶瘤株，這是一種感染和破壞腫瘤細胞的改良單純皰疹病毒 (HSV)，用於治療皮膚黑色素瘤。由於病毒療法、T-VEC (Imlyg) 等新產品的批准，預計在預測期內（2022-2029 年）它將主導全球市場。根據世界衛生組織的數據，全世界每年有 2 到 300 萬例非黑色素瘤皮膚癌和 132,000 例黑色素瘤皮膚癌。根據皮膚癌基金會的統計，五分之一的美國人在其一生中會患上皮膚癌。隨著臭氧層的消耗，大氣失去了越來越多的保護過濾功能，讓更多的太陽紫外線輻射到達地表。據估計，臭氧水平降低 10% 會導致 300,000 多例非黑色素瘤皮膚癌和 4,500 多例黑色素瘤。根據世界癌症研究基金國際組織的數據，皮膚黑色素瘤是世界上第 17 位最常見的癌症，2020 年有超過 150,000 例新發黑色素瘤病例。根據皮膚癌基金會的數據，美國每天有超過 9,500 人被診斷出患有皮膚癌。

區域分析

北美地區擁有世界上最大的溶瘤病毒治療市場。

北美將在 2021 年主導全球溶瘤皮膚癌市場。由於癌症負擔增加、研發重點和支出增加以及北美主要市場參與者的存在，預計該地區將在整個預測期間（2022-2029 年）佔據主導地位。根據美國國家癌症中心的數據，2020 年有 1,806,590 人新診斷出患有癌症，有 606,520 人死於癌症。根據美國癌症協會的數據，到 2021 年，將有大約 190 萬人被診斷出患有這種疾病，608,570 人將死於這種疾病。疾病預防控制中心預測，到 2040 年，每年將有 2950 萬新癌症病例。此外，北美擁有最強大和最先進的醫療基礎設施以及更好的醫療報銷政策，這有助於北美在預測期內主導全球市場。

競爭格局

溶瘤病毒治療高度集中在Amgen Inc.、Shanghai Sunway Biotech Co. Ltd、RIGVIR 等少數主要參與者中。該行業的公司以低利潤率運營，在預測期內可能會進一步惡化。行業參與者正專注於實施無機增長戰略以擴大其市場佔有率。例如，2022 年 1 月 11 日，Amgen 和 Arrakis Therapeutics 合作確定了新型 RNA 降解小分子療法。

Amgen Inc.

概述

Amgen, Inc. 成立於 1980 年，總部位於加利福尼亞州千橡市，是一家領先的跨國生物製藥公司。 Amgen 專注於分子生物學和生化產品的研究和製造，目標是提供基於重組 DNA 技術的醫療保健業務。

產品組合

Amgen 的溶瘤病毒治療產品組合包括 IMLYGIC (talimogene laherparepvec)，一種單純皰疹病毒 1 的減毒形式。

全球溶瘤病毒療法市場報告將提供對大約 40 多個市場數據表、45 多個數字和 200 多頁（大約）的訪問。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 研發
      • 癌症患者增加
    • 約束因素
      • 高成本
      • 免疫反應
    • 商機
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析
  • 管道分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按治療類別

  • Onxy-15
  • Tarimo Genra Herpa Repbeck
  • 重鹼
  • 吊鉤
  • 其他

第 8 章按應用程序

  • 黑色素瘤
  • 卵巢癌
  • 乳腺癌
  • 其他

第 9 章按治療類型

  • 使用 HSV 的溶瘤病毒
  • 腺病毒腫瘤病毒
  • 牛痘病毒抗癌劑
  • 基於水皰性口炎病毒的溶瘤病毒
  • 來源於新城疫病毒的溶瘤病毒

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 12 章公司簡介

  • Amgen Inc.
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Shanghai Sunway Biotech Co. Ltd
  • RIGVIR

第 13 章數據M

簡介目錄
Product Code: DMPH100

Market Overview

Oncolytic Virus Therapy Market is expected to grow at a CAGR of 19.32% in the forecast period (2022-2029).

An oncolytic virus is a genetically engineered or naturally occurring virus that can imitate selected terms and kill cancer cells without harming normal tissues. Oncolytic Virus therapy is a new therapeutic approach for treating cancer and has shown promising results globally.

Market Dynamics

The rising prevalence of cancer cases and increasing development of cancer-treating therapies such as an oncolytic virus is driving the market growth globally.

The increasing number of cancer cases and clinical research propel the global oncolytic virus therapy market growth.

The growing cases of cancer and increasing clinical research on oncolytic virus therapy fuel the global market growth. For instance, according to the Clinical Trials. Gov, 10 interventional clinical studies are active; a few of them are Phase II window of opportunity trial of stereotactic body radiation therapy and in situ oncolytic virus therapy in metastatic triple-negative breast cancer and metastatic non-small cell lung cancer followed by Pembrolizumab sponsored by The Methodist Hospital Research Institute and estimated to be finished by November 2023, a phase I/II study of Pexa-Vec oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer sponsored by National Cancer Institute (NCI) and expected to be finished by June 2023 and a phase 1b & 2 study with GL-ONC1 oncolytic immunotherapy in patients with recurrent or refractory ovarian cancer (VIRO-15) sponsored by Genelux Corporation and completion date estimation is December 2022.

Furthermore, per the WHO statistics, cancer accounted for 10 million deaths in 2020, about 1 in 6 deaths from cancer. Out of which, around 70% of deaths occurred in low- and middle-income countries; the most common type of cancer are breast (2.26 million cases in 2020), lung (around 2.21 million cases in 2020), and colon & rectum cancers (1.93 million cases in 2020).

The high cost and immune reaction restrain the growth of the market.

The immune reaction to the virus-based therapies by repeated administration of therapeutics for treating cancer is a critical restraint hampering the market growth. The high cost of oncolytic virus therapy further affects market growth, especially in developing countries.

COVID-19 Impact

COVID-19 had a positive impact on the market by creating improved opportunities. For instance, COVID-19 has steered our focus towards biotechnologically modified products to achieve better results. Amidst the pandemic, many biopharmaceutical industries developed different biotechnologically modified vaccines to treat and diagnose SARS-CoV-2 to win over the pandemic. Moreover, biotechnological devices have helped in the various stages of fighting the pandemic; the COVID-19 pandemic has made us look at biotechnological solutions for a better healthcare system, which had an affirmative effect on the immunotoxin market.

Segment Analysis

The melanoma segment is assumed to command the global market throughout the forecast period (2022-2029).

Melanoma is expected to dominate the global market during the forecast period (2022-2029) owing to the growing burden of skin melanoma and new product approvals, such as FDA currently approved an oncolytic virus therapy for the treatment of skin melanoma, T-VEC (Imlygic), a modified herpes simplex virus (HSV) that infects tumor cells and promotes their destruction. Also, as per the WHO, annually 2 to 3 million non-melanoma skin cancers and 132,000 melanoma skin cancers occur globally. One in every three cancers diagnosed is a skin cancer; according to Skin Cancer Foundation Statistics, one in every five Americans will develop skin cancer in their lifetime. As the ozone levels are depleted, the atmosphere loses more and more of its protective filter function, and more solar UV radiation reaches the Earth's surface. An estimated 10 percent decrease in ozone levels will result in an additional 300,000 non-melanoma and 4,500 melanoma skin cancer cases. According to the World Cancer Research Fund International, skin melanoma is the 17th most common cancer worldwide; there were more than 150,000 new melanoma cases in 2020. In reference to the Skin Cancer Foundation, in the U.S., more than 9,500 people are diagnosed with skin cancer every day.

Geographical Analysis

The North American region holds the largest global oncolytic virus therapy market.

North America dominated the global oncolytic skin cancer market in 2021. It is estimated to dominate throughout the forecast period (2022-2029) since there is a growing burden of cancer in this region, along with the increased focus and spending on research and development and the presence of key market players in North America. According to the National Cancer Institute, in 2020, 1,806,590 new cases were diagnosed, with 606,520 deaths registered of cancer. In addition, in 2021, around 1.9 million were diagnosed, and 608,570 deaths were confirmed of cancer, as per the American Cancer Society. According to the projection by CDC, new cancer cases per year will rise to 29.5 million by 2040. Moreover, North America has the most robust and advanced healthcare infrastructure, along with better healthcare cost reimbursement policies, which helps North America to dominate the global market during the forecast period.

Competitive Landscape

Oncolytic virus therapy is highly concentrated among a few key players, such as Amgen, Shanghai Sunway Biotech Co. Ltd, and RIGVIR. Companies in the industry operate on low-profit margins, which are likely to worsen further during the forecast period. Industry players are focusing on implementing inorganic growth strategies to expand their presence in the market. For instance, on 11 January 2022, Amgen and Arrakis Therapeutics collaborated to identify novel RNA degrader small molecule therapeutics.

Amgen Inc.

Overview:

Amgen Inc. is a leading multinational biopharmaceutical company founded in 1980 and headquartered in Thousand Oaks, California. Amgen Inc. is focused on research and manufacturing molecular biology and biochemistry products; its goal is to provide a healthcare business based on recombinant DNA technology.

Product Portfolio:

The product portfolio of Amgen Inc. for oncolytic virus therapy has IMLYGIC (talimogene laherparepvec) is a weakened form of Herpes Simplex Virus Type 1.

The global oncolytic virus therapy market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Research and Development
      • 4.1.1.2. Increasing Prevalence of Cancer Cases
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost
      • 4.1.2.2. Immune Reaction
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pipeline Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Onxy-15
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Talimogene laherparepvec
  • 7.4. Reolysin
  • 7.5. RIGVIR
  • 7.6. Others

8. By Applications

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Melanoma
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Ovarian Cancer
  • 8.4. Breast Cancer
  • 8.5. Others

9. By Therapy Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 9.1.2. Market Attractiveness Index, By Therapy Type
  • 9.2. HSV-based Oncolytic Viruses
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Adenoviruses-based Oncolytic Viruses
  • 9.4. Vaccinia Virus-based Oncolytic Viruses
  • 9.5. Vesicular Stomatitis Virus-based Oncolytic Viruses
  • 9.6. Newcastle Disease Virus-based Oncolytic Viruses

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Amgen Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Shanghai Sunway Biotech Co. Ltd
  • 12.3. RIGVIR

LIST NOT EXHAUSTIVE

13. DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us